Showing 3181-3190 of 5646 results for "".
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- BJO Publishes New Data on Clearside Biomedical’s Investigational Treatment Xiperehttps://modernod.com/news/bjo-publishes-new-data-on-clearside-biomedicals-investigational-treatment-xipere/2478989/New data has been published in The British Journal of Ophthalmology related to the clinical development program of Clearside Biomedical’s Xipere, an investigational treatment with a proposed indication of macular edema associated with noninfectious uveitis.
- New Study Finds Significant Improvements in DED Following Use of Eye Eco Tranquileyes XL and Tranquilvibes Hydrating Maskshttps://modernod.com/news/new-study-finds-significant-improvements-in-ded-following-use-of-eye-eco-tranquileyes-xl-and-tranquilvibes-hydrating-masks/2478984/Eye Eco announced results of a study validating the clinical benefits of its moist heat masks, Tranquilvibes and Tranquileyes XL, for improving the signs and symptoms of dry eye disease caused by meibomian gland dysfunction (MGD). Patients who used the masks to treat tired, dry, gritty, inflamed
- The World Council of Optometry and CooperVision Partner to Define a Standard of Care to Treat Myopia Progressionhttps://modernod.com/news/the-world-council-of-optometry-and-coopervision-partner-to-define-a-standard-of-care-to-treat-myopia-progression/2478985/The World Council of Optometry (WCO) and CooperVision have announced a global partnership to raise awareness of myopia progression and encourage optometrists to embrace a standard of care to manage the condition. “Myopia is arguably the most widespread epidemic faced by the global optometr
- Studies Demonstrate the Efficacy and Safety of Eyenovia MAP Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasishttps://modernod.com/news/studies-demonstrate-the-efficacy-and-safety-of-eyenovia-map-fixed-combination-tropicamide-phenylephrine-product-for-mydriasis/2478982/Eyenovia announced the publication of “
- NIH-Led Team Sets New Bar in Retinal Imaginghttps://modernod.com/news/nih-led-team-sets-new-bar-in-retinal-imaging/2478963/A team led by scientists at the National Eye Institute (NEI) has noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. Published in Optica, the researchers report how they improved imaging resolution by a thi
- CORE Offers Tips on Seeking Eye Care During the Pandemic, Provides Free Infographics for ECPs to Use with Patientshttps://modernod.com/news/core-offers-tips-on-seeking-eye-care-during-the-pandemic-provides-free-infographics-for-ecps-to-use-with-patients/2478959/As the global COVID-19 pandemic enters its second year, a new initiative from the Centre for Ocular Research & Education (CORE) is addresses questions that may keep people from seeking proper eye care. CORE has designed
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-mira-1-phase-2b-results-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol/2478940/Ocuphire Pharma announced that the results from the MIRA-1 (NCT04024891) phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal of mydriasis have been published in Optometry and Visual Science. The article will appear in the print edition and is available on-
- Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trialhttps://modernod.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-denali-phase-3-trial/2478936/Nicox SA announced that its partner, Ocumension Therapeutics, has received approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct
- Ophtec: Tiny ID Matrix Code Enables Fast Delivery of Premium IOLshttps://modernod.com/news/ophtec-tiny-id-matrix-code-enables-fast-delivery-of-premium-cataract-iols/2478885/Ophtec announced it has recently integrated a laser marking technology in the production process of its premium cataract IOLs. A micro ID matrix code is imprinted in the IOLs loop junctions by the laser. Using this code, special scanners can identify the IOL